Considering the personal, societal, and economic toll of treatment-resistant depression, we must make it easier to access medicines and care that provide value, both for the patient and for the health care system.
Kruti Joshi, MPH
Advertisement
Kruti Joshi, MPH, Director, Real World Value & Evidence, Janssen Pharmaceuticals, Inc.
Articles by Kruti Joshi, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Measles Outbreaks Cause Financial, Public Health Burden in US
3
Immunotherapy's Evolving Role in Ovarian Cancer: Nicoletta Colombo, MD, PhD
4
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
5
